NASDAQ: COO · Medical Instruments & Supplies

Cooper Companies (COO) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Cooper Companies (COO) at $70.88 a share. The stock last closed at $61.88, which puts the model's fair value 14.5% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. The Cooper Companies, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$70.88midpoint of 2,000 simulations
Last close$61.88NASDAQ: COO
Gap to fair value+14.5%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 held the fair value at $70.88, within 1% of the run of 7 Nov 2026.

What the model makes of itThe price of $61.88 is 14.5% below it: Fairly valued, on a high evidence grade.

What's nextReports on 3 Dec 2026. Options prices imply a move of about 14% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give COO?

The calibrated range for COO over 63 trading days is $53.00 to $72.82. It sits around the last close, and its width comes from the volatility that COO's own options imply (47% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $58.03 to $84.97. In 69% of the simulations the fair value came out above the price the model ran on.

$45.38$107.66
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $70.88. Dashed line: the last close, $61.88.

Faircurve Insights · 14 Nov 2026

The Cooper Companies, Inc. (COO) is a global medical device firm. It develops, produces and distributes products through two business units, CooperVision and CooperSurgical, and CooperVision specialises in contact lenses.

Faircurve's model put the fair value at $70.88 a share on 14 Nov 2026. That is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $70.57, so the fair value moved +0.4%. The calibrated range over 63 trading days is $53.66 to $73.72. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices, using 8,038 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

The model's overall quality score is 55 out of 100, a composite of six factors scored against comparable companies. Stability stands out at 100, with five-year EBITDA margin downside volatility of 0.9 pts against a peer median of 1.9 pts. Profitability scores 68, with ROIC of 5.1% against a peer median of 3.3%. The model compares the company with Repligen Corporation, Baxter International, Avantor, Solventum, AptarGroup, Teleflex, Merit Medical Systems and West Pharmaceutical Services.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does COO report earnings, and how has the stock reacted?

Cooper Companies's next earnings report is scheduled for 3 Dec 2026. Companies can move their dates.

On 16 Nov 2026, COO's 30 day implied volatility worked out to a move of about 13.6% over one month, in either direction. That is a size, not a direction.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across COO's last 8 reports, ignoring direction, was 9.4%.

0%5%10%15%20%9.1%6.0%5 Dec '247.5%6.9%6 Mar '25no quote14.8%29 May '25no quote12.3%27 Aug '2511.0%7.1%4 Dec '259.8%6.6%5 Mar '2615.2%11.6%4 Jun '269.8%20.0%9 Sep '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in COO

5%10%15%20%9 Sep '26 report4 Jun '26 report5 Mar '26 report4 Dec '25 report14% at 12 Nov '2613 Nov '2512 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 13% on 13 Nov 2025, reached 17% on 29 May 2026 and reads 14% on 12 Nov 2026. The marks are report dates.

How does COO score on business quality?

Cooper Companies's overall quality score is 55 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.685.1%ROIC3.3%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).521.19xFCF / net income1.42x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.365.1%Revenue growth, trailing5.7%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.380.5%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.382.62xNet debt / EBITDA1.49x
StabilityDownside volatility of the EBITDA margin over the last five years.1000.9 ptsEBITDA margin downside volatility, 5y1.9 pts

How does COO compare with similar companies?

The companies in medical instruments & supplies closest to Cooper Companies in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
RGEN Repligen Corporation$162.78$152.66-6.2%Fairly valued
BAX Baxter International Inc.$25.54$24.84-2.7%Fairly valued
AVTR Avantor, Inc.$15.32$20.70+35.1%Undervalued
SOLV Solventum Corporation$88.65$88.47-0.2%Fairly valued
ATR AptarGroup, Inc.$143.17$137.10-4.2%Fairly valued
TFX Teleflex Incorporated$157.10$169.00+7.6%Fairly valued
MMSI Merit Medical Systems, Inc.$86.35$82.63-4.3%Fairly valued
WST West Pharmaceutical Services, Inc.$417.80$372.00-11.0%Fairly valued

What the comparable companies' multiples alone would give for COO, the peer-implied price, is $80.81 a share on this run. The fair value weighs that against the company's own multiple.

All medical instruments & supplies stocks ranked by gap to fair value

Cooper Companies at a glance

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses.

Market value
$11.9B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Revenue expected, next twelve months
$4.4B
Consensus revenue growth, next fiscal year
+3.6%
Analysts with estimates
11
Beta to the US market
0.36
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. COO was among them.

How the fair value is worked out: the model prices Cooper Companies on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for COO was $70.57. As of 14 Nov 2026 it is $70.88, a change of +0.4%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Cooper Companies's valuation

Is Cooper Companies stock undervalued or overvalued?

On Faircurve's model, COO reads as Fairly valued as of 14 Nov 2026. The model's fair value is $70.88 a share against a last close of $61.88, a gap of +14.5%.

What is COO's fair value?

$70.88 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $58.03 to $84.97.

What price range does the model give COO?

$53.00 to $72.82 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Cooper Companies report earnings next?

The next report is scheduled for 3 Dec 2026. Companies can move their dates.

How much has COO moved on past earnings reports?

Across its last 8 reports the median two session move was 9.4%, ignoring direction. The largest was -20.0% around the report of 9 Sep 2026.

How confident is the model in this valuation?

The model's evidence grade for COO is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on COO

The model holds no idea open on COO today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on COO with their outcomes. A free account is enough.

Keep reading